Bio2Brain is a project funded by the European Union that focuses on the delivery of biopharmaceuticals from the nose to the brain for the treatment of central nervous system diseases. The primary objective of the Bio2Brain network is to establish a comprehensive research and training program aimed at educating young scientists in developing innovative technologies for efficient delivery of biopharmaceuticals to the brain through the nasal route. This initiative provides a unique opportunity for 13 early career researchers to explore new approaches and therapies for neurological diseases. Moreover, Bio2Brain aims to lay the foundation for future translation of these technologies into clinical development and Good Manufacturing Practice (GMP).

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 956977.